Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is an oncology-focused medical technology company whose news flow centers on its Pressure-Enabled Drug Delivery (PEDD) platform, TriNav infusion systems and the clinical and commercial progress of its solid tumor programs. Company updates frequently highlight revenue trends tied to adoption of the TriNav product suite in liver-directed therapies, as well as broader use of PEDD-based embolization techniques in new clinical settings.
Investors and observers following TLSI news can expect regular earnings releases and operational updates that discuss net sales from the TriNav system, gross margin dynamics, operating expenses and changes in capital structure, including exchange offers and preferred stock conversions described in SEC filings. These releases often emphasize growing clinical adoption of PEDD technology across a range of solid tumor indications and note the company’s focus on the interventional radiology specialty.
TriSalus also issues news about clinical and scientific developments. Examples include publication of data on Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav Infusion System for symptomatic thyroid disease, initiation of a clinical trial evaluating genicular artery embolization for knee osteoarthritis, and registry efforts such as the PROTECT study. The company additionally announces key opinion leader events that review the use of TriNav in thyroid and uterine artery embolization and discuss unmet needs in these areas.
Another recurring category of TLSI news involves participation in healthcare and growth conferences, where management provides corporate overviews and meets with investors. Together, these earnings updates, clinical data announcements, KOL events and conference appearances provide a detailed view of how TriSalus is advancing and commercializing its PEDD technology and investigational immunotherapy. Bookmarking the TLSI news page offers a centralized way to follow these developments over time.
TriSalus Life Sciences (Nasdaq: TLSI) announced the completion of its exchange offer and consent solicitation for warrants. The offer expired on June 25, 2024, allowing holders to exchange warrants for common stock. Approximately 78.89% of public warrants were tendered, but the company did not secure agreements for private placement or working capital warrants. The company will accept all validly tendered warrants for exchange by July 1, 2024. The warrant amendment was approved for public warrants, but not for private placement or working capital warrants. Oppenheimer & Co. served as the dealer manager and solicitation agent.
TriSalus Life Sciences (NASDAQ: TLSI) presented clinical data from its Phase 1b PERIO-02 trial at the ASCO 2024 Annual Meeting. The trial studies the hepatic arterial infusion (HAI) of nelitolimod using TriSalus's proprietary Pressure Enabled Drug Delivery (PEDD) technology in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The 4 mg dose showed promising results with all three patients achieving disease control, including one complete response, one partial response, and one stable disease. Follow-up is ongoing to determine the next steps. The PEDD method aims to improve drug delivery within tumor microenvironments, potentially enhancing treatment efficacy. Median progression-free survival for the 4 mg dose was over 120 days. The study also noted significant immune responses, including increased CD4 and CD8 T cells in liver tumors.
TriSalus Life Sciences (NASDAQ: TLSI), an oncology company, announced an exchange offer and consent solicitation for its various warrants. The initiative aims to simplify the capital structure and reduce the dilutive impact of these warrants. Holders of the Public Warrants, Private Placement Warrants, and Working Capital Warrants are offered to exchange their warrants for 0.30 shares of common stock per warrant. If adopted, the Warrant Amendment will require outstanding warrants to be exchanged at 0.27 shares per warrant. The offer involves up to 4,264,532 shares of common stock and seeks consents from warrant holders to amend the warrant agreements. The offer expires on June 25, 2024, and is managed by Oppenheimer & Co. Inc.
TriSalus Life Sciences (Nasdaq: TLSI) reported its Q1 2024 financial results, highlighting a 116% year-over-year revenue increase to $6.5 million, driven by the TriNav® Infusion System. The gross margin improved to 85%, up from 78% in Q1 2023. Despite increased investments leading to an operating loss of $11.7 million and a net loss of $13.2 million, the company secured up to $50 million in debt financing with OrbiMed. Additionally, TriSalus appointed Liselotte Hyveled to its Board of Directors. The company forecasts full-year sales growth to exceed 50%.
TriSalus Life Sciences, a Nasdaq-listed oncology company, appointed Liselotte Hyveled to its Board of Directors. Hyveled, an industry veteran with over two decades of experience in pharmaceutical research and development, will contribute to TriSalus' vision of pioneering innovative treatments for liver and pancreatic cancers. Her strategic insights and patient-centric approach will be important in shaping the company's growth trajectory and advancing its technology and therapeutic pipelines.
TriSalus Life Sciences, a Nasdaq-listed oncology company, will host a conference call on May 15, 2024, at 9:00 a.m. ET to discuss first-quarter financial results and provide a business update. The call will cover the period ending March 31, 2024, and will be webcast live on their investor relations website.
TriSalus Life Sciences has secured up to $50 million in debt financing with OrbiMed to support the growth of its TriNav® Infusion System. $25 million was funded initially, with an option for an additional $25 million based on revenue thresholds. The financing is expected to fuel strategic expansion, extending the cash runway through 2025.
Summary not available.
Summary not available.
Summary not available.